Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.

Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH.

BMC Infect Dis. 2013 Apr 27;13:190. doi: 10.1186/1471-2334-13-190.

2.

Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.

Elbasha EH, Chhatwal J, Ferrante SA, El Khoury AC, Laires PA.

Appl Health Econ Health Policy. 2013 Feb;11(1):65-78. doi: 10.1007/s40258-012-0007-8.

PMID:
23355388
3.

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH.

Value Health. 2013 Sep-Oct;16(6):973-86. doi: 10.1016/j.jval.2013.07.006.

4.

Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.

Dan YY, Ferrante SA, Elbasha EH, Hsu TY.

Antivir Ther. 2015;20(2):209-16. doi: 10.3851/IMP2825. Epub 2014 Aug 8.

PMID:
25105844
5.

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.

Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J.

Clin Ther. 2015 Jul 1;37(7):1529-40. doi: 10.1016/j.clinthera.2015.05.003. Epub 2015 May 29.

PMID:
26031617
6.

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.

Blázquez-Pérez A, San Miguel R, Mar J.

Pharmacoeconomics. 2013 Oct;31(10):919-31. doi: 10.1007/s40273-013-0080-3.

PMID:
24000086
7.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
8.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.

J Med Econ. 2014 Jan;17(1):77-87. doi: 10.3111/13696998.2013.844159. Epub 2013 Nov 21.

PMID:
24032626
9.

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.

Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, Gasbarrini A, Bruno S, Craxì A, Cammà C; WEF study group.

Dig Liver Dis. 2014 Oct;46(10):936-42. doi: 10.1016/j.dld.2014.06.009. Epub 2014 Jul 23.

PMID:
25066806
10.

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.

Cure S, Bianic F, Gavart S, Curtis S, Lee S, Dusheiko G.

J Med Econ. 2014 Jan;17(1):65-76. doi: 10.3111/13696998.2013.860033. Epub 2013 Nov 18.

PMID:
24160335
11.

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group.

J Hepatol. 2013 Oct;59(4):658-66. doi: 10.1016/j.jhep.2013.05.019. Epub 2013 May 23.

PMID:
23707373
12.
13.

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators.

Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6. Erratum in: Lancet. 2010 Oct 9;376(9748):1224. SPRINT-1 investigators [added]; multiple investigator names added.

PMID:
20692693
14.

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.

Westerhout K, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J.

J Med Econ. 2015;18(10):838-49. doi: 10.3111/13696998.2015.1044457. Epub 2015 Jul 6.

PMID:
25903830
15.

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM.

Liver Int. 2014 May;34(5):707-19. doi: 10.1111/liv.12300. Epub 2013 Oct 9.

PMID:
24118703
16.

Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.

Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH.

J Hepatol. 2013 Mar;58(3):479-87. doi: 10.1016/j.jhep.2012.11.020. Epub 2012 Nov 23.

PMID:
23183529
17.

Boceprevir for previously treated chronic HCV genotype 1 infection.

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.

18.

Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.

Vellopoulou A, van Agthoven M, van der Kolk A, de Knegt RJ, Berdeaux G, Cure S, Bianic F, Lamotte M.

Appl Health Econ Health Policy. 2014 Dec;12(6):647-59. doi: 10.1007/s40258-014-0120-y.

PMID:
25103219
19.

Boceprevir for untreated chronic HCV genotype 1 infection.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.

20.

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.

Turnes J, Romero-Gómez M, Planas R, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Rubio-Terrés C, Ventayol P.

Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9.

PMID:
24119723

Supplemental Content

Support Center